AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26367736 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin plus vitamin E (2 tablets per day) and hypocaloric diet (1520 kcal, 52% carbohydrates, 25% lipids, 23% proteins) for 3 months
Number of subjects: 36
Study 26367736 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet only
Number of subjects: 36
Study 23245336 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m² on day 1) and Cisplatin (25 mg/m² on days 2 and 4) with regional hyperthermia (1 hour on days 2 and 4) biweekly for 4 months
Number of subjects: 23
Study 22014122 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted case management using the FORA system coupled with nurse case management
Number of subjects: 200
Study 22014122 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 19673597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloxacillin (1.0 g intravenous dose, 30 min prior to operation)
Number of subjects: 292
Study 19673597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion, 30 min prior to operation)
Number of subjects: 292
Study 17022367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold ceramic
Number of subjects: 40
Study 17022367 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer
Number of subjects: 40
Study 12644419 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micro g fentanyl epidurally
Number of subjects: 30
Study 12644419 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micro g fentanyl epidurally
Number of subjects: 30
Study 12644419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10690937 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 50 microg intravenous (IV) injection
Number of subjects: 8
Study 10690937 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine GAL 500 microg infusion from -10 to +30 minutes
Number of subjects: 8
Study 10690937 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 9062857 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocheck
Number of subjects: 19
Study 9062857 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioscan
Number of subjects: 19
Study 9062857 — intervention group
Group type: COMPARATOR
Intervention: Composite clinical assessment
Number of subjects: 19
Study 8456753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 0.05 mg/kg intravenous bolus followed by 0.2 mg/kg/hour intravenous infusion
Number of subjects: 45
Study 8456753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 0.15 mg/kg intravenous bolus followed by 0.6 mg/kg/hour intravenous infusion
Number of subjects: 45
Study 8456753 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5,000 U intravenous bolus
Number of subjects: 45
Study 2941687 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 773
Study 2941687 — intervention group
Group type: EXPERIMENTAL
Intervention: Second series of vaccinations
Number of subjects: 773
Study 30281698 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 89
Study 30281698 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic surgery
Number of subjects: 89
Study 30281698 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 27688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of depressed mothers
Number of subjects: 114
Study 27688075 — intervention group
Group type: COMPARATOR
Intervention: Infants of nondepressed mothers
Number of subjects: 114
Study 27688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease by biomarker analyses using GeneGo MetaCore Software
Number of subjects: 114
Study 27688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Process networks analysis
Number of subjects: 114
Study 23913020 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective coiling
Number of subjects: 14
Study 23913020 — intervention group
Group type: COMPARATOR
Intervention: Parent artery occlusion
Number of subjects: 14
Study 23913020 — intervention group
Group type: COMPARATOR
Intervention: Selective coiling and Parent artery occlusion
Number of subjects: 14
Study 22437068 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 51
Study 22437068 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug treatment)
Number of subjects: 51
Study 20386216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implant anchorage
Number of subjects: 14
Study 20386216 — intervention group
Group type: COMPARATOR
Intervention: Molar anchorage (non-implant)
Number of subjects: 14
Study 18343487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 30
Study 18343487 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM)
Number of subjects: 30
Study 15083355 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative morphine sulfate plus lidocaine administered as a local spray
Number of subjects: 60
Study 15083355 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine applied alone
Number of subjects: 60
Study 12429761 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical compression device
Number of subjects: 100
Study 12429761 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic stockings
Number of subjects: 100
Study 10488967 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E phenotype E2 carriers
Number of subjects: 822
Study 10488967 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E phenotype E4 carriers
Number of subjects: 822
Study 10488967 — intervention group
Group type: COMPARATOR
Intervention: Apolipoprotein E phenotype E3/3 homozygotes
Number of subjects: 822
Study 8709630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy according to NOPHO AML protocols
Number of subjects: 20
Study 8709630 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation (BMT) without prior chemotherapy
Number of subjects: 20
Study 2008691 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 7
Study 2008691 — intervention group
Group type: COMPARATOR
Intervention: Gluten (provocation)
Number of subjects: 7
Study 6189439 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corticotherapy
Number of subjects: 130
Study 6189439 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 130
Study 6189439 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin, blocking agents, intravenous clomipramine, periarterial injections of local anaesthetics, local or general corticotherapy, physiotherapy, kinesitherapy
Number of subjects: 130
Study 6189439 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesitherapy
Number of subjects: 130
Study 31370896 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (SC - 0.5 g.kg‐1BM in capsules of 500 mg)
Number of subjects: 10
Study 28381584 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) with aspirin + a P2Y12 inhibitor
Number of subjects: 9240
Study 26390721 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (auto-HSCT) after non-myeloablative BEAM conditioning
Number of subjects: 90
Study 26390721 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (non-auto-HSCT group)
Number of subjects: 90
Study 26390721 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-HSCT
Number of subjects: 90
Study 26390721 — intervention group
Group type: COMPARATOR
Intervention: Non-auto-HSCT
Number of subjects: 90
Study 23958795 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg/kg of alcohol
Number of subjects: 32
Study 23958795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21851764 — intervention group
Group type: COMPARATOR
Intervention: Training intervention for healthcare professionals (HCPs)
Number of subjects: 693
Study 21851764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 693
Study 19530070 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR transmission mode
Number of subjects: 0
Study 19530070 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR transmission
Number of subjects: 0
Study 19530070 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR Quantification
Number of subjects: 0
Study 17261336 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic postal reminders to see their general practitioner every three months during a 3-year follow-up.
Number of subjects: 983
Study 17261336 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 983
Study 14692040 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week cognitive-behavioral stress management (CBSM) intervention
Number of subjects: 92
Study 14692040 — intervention group
Group type: COMPARATOR
Intervention: 1-day seminar (control group)
Number of subjects: 92
Study 12150516 — intervention group
Group type: EXPERIMENTAL
Intervention: High Bcl-2 expression
Number of subjects: 47
Study 12150516 — intervention group
Group type: EXPERIMENTAL
Intervention: High Bcl-XL expression
Number of subjects: 47
Study 12150516 — intervention group
Group type: EXPERIMENTAL
Intervention: High Bax expression
Number of subjects: 47
Study 9814091 — intervention group
Group type: EXPERIMENTAL
Intervention: tenoxicam 20 mg daily for six weeks
Number of subjects: 48
Study 9814091 — intervention group
Group type: COMPARATOR
Intervention: piroxicam 20 mg daily for six weeks
Number of subjects: 48
Study 7542109 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 6 months
Number of subjects: 46
Study 7542109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2649213 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol-17-propionate cream
Number of subjects: 10
Study 1087383 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐5‐hydroxytryptophan (alone or in combination with carbidopa)
Number of subjects: 4
Study 1087383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30572162 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive-behavior therapy (CCBT)
Number of subjects: 240
Study 30572162 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 240
Study 26464212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (79% prescribed insulin, mean total daily dose 0.41 units/kg)
Number of subjects: 10163
Study 26464212 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (62% prescribed insulin, mean total daily dose 0.30 units/kg)
Number of subjects: 10163
Study 26464212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin
Number of subjects: 10163
Study 26464212 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose after adjustment for covariates
Number of subjects: 10163
Study 23542800 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy (tidal volume of 7 ml/kg ideal body weight, 10 cm H2O positive end-expiratory pressure, and recruitment maneuvers)
Number of subjects: 56
Study 23542800 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation strategy (tidal volume of 9 ml/kg ideal body weight and zero-positive end-expiratory pressure)
Number of subjects: 56
Study 23542800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 21771797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer (HR)
Number of subjects: 120
Study 21771797 — intervention group
Group type: COMPARATOR
Intervention: clear overlay retainer (COR)
Number of subjects: 120
Study 19874247 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants and hormonal supplements
Number of subjects: 19
Study 19874247 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 19
Study 19874247 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 19
Study 19874247 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label studies
Number of subjects: 19
Study 17085763 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care treatment model
Number of subjects: 8367
Study 17085763 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment initiation
Number of subjects: 8367
Study 17085763 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of research adherence and treatment initiation
Number of subjects: 8367
Study 14727010 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 (n=31)
Number of subjects: 66
Study 14727010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 11758675 — intervention group
Group type: EXPERIMENTAL
Intervention: agalsidase alfa (human alpha‐Gal A)
Number of subjects: 26
Study 9466067 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin continued (17 patients, 85%)
Number of subjects: 20
Study 9466067 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin group
Number of subjects: 20
Study 9466067 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-warfarin)
Number of subjects: 20
Study 7946924 — intervention group
Group type: EXPERIMENTAL
Intervention: Brewer's yeast
Number of subjects: 22
Study 7946924 — intervention group
Group type: COMPARATOR
Intervention: Torula yeast
Number of subjects: 22
Study 3279916 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg phospholipid given intratracheally (treatment group)
Number of subjects: 29
Study 3279916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 29
Study 31487797 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir (180 mL/day)
Number of subjects: 22
Study 31487797 — intervention group
Group type: COMPARATOR
Intervention: Unfermented milk (control)
Number of subjects: 22
Study 28104555 — intervention group
Group type: EXPERIMENTAL
Intervention: Gossip conversation
Number of subjects: 22
Study 28104555 — intervention group
Group type: COMPARATOR
Intervention: Emotional non-gossip conversation
Number of subjects: 22
Study 28104555 — intervention group
Group type: COMPARATOR
Intervention: Neutral conversation
Number of subjects: 22
Study 26025412 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive pill + flare-up GnRH‐agonist protocol (P2)
Number of subjects: 440
Study 26025412 — intervention group
Group type: COMPARATOR
Intervention: GnRH‐antagonist protocol (P3)
Number of subjects: 440
Study 24273972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at bilateral Neiguan (PC6) and Xinshu (BL15) for 30 min, frequency of 2/15 Hz, current strength 9 - 18 mA
Number of subjects: 59
Study 24273972 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerine (1 mg sublingual administration)
Number of subjects: 59
Study 22005860 — intervention group
Group type: COMPARATOR
Intervention: Independent exercises
Number of subjects: 94
Study 22005860 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 94
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (1‐34 PTH)
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐84 PTH
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two or more drugs
Number of subjects: 0
Study 19484202 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH followed by bisphosphonates
Number of subjects: 0
Study 16430313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (12, 24, 36, and 60mg on separate days)
Number of subjects: 66
Study 16430313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (12, 24, and 36mg on separate days)
Number of subjects: 66
Study 16430313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 14634679 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat and lifestyle modification (OLM)
Number of subjects: 108
Study 14634679 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 108
Study 10607279 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Question Grid
Number of subjects: 67
Study 10607279 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 67
Study 8626358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (200 to 600 mg/day)
Number of subjects: 128
Study 8626358 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (100 to 300 mg/day)
Number of subjects: 128
Study 8626358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 to 6 capsules/day)
Number of subjects: 128
Study 1627372 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2 (300 micrograms/m2)
Number of subjects: 22
Study 1627372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant interleukin-2 (300 micrograms/m2)
Number of subjects: 22
Study 1627372 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2
Number of subjects: 22
Study 1627372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant interleukin-2
Number of subjects: 22
Study 6201999 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 75
Study 6201999 — intervention group
Group type: COMPARATOR
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 75
Study 6201999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TURP and TVP
Number of subjects: 75
Study 31234642 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 616
Study 31234642 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 616
Study 31234642 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 30 mg
Number of subjects: 616
Study 31234642 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 10 mg
Number of subjects: 616
Study 31234642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 29363715 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment
Number of subjects: 0
Study 29363715 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 27334131 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA + DEX
Number of subjects: 196
Study 27334131 — intervention group
Group type: COMPARATOR
Intervention: APR + PALO + DEX
Number of subjects: 196
Study 24269255 — intervention group
Group type: COMPARATOR
Intervention: Fasted/Food Absence
Number of subjects: 67
Study 24269255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted/Food Exposure
Number of subjects: 67
Study 24269255 — intervention group
Group type: COMPARATOR
Intervention: Fed/Food Absence
Number of subjects: 67
Study 24269255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed/Food Exposure
Number of subjects: 67
Study 22465890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythropoietin (20,000 unit/24 hours) for 5 consecutive days along with intravenous methyl prednisolone (1000 mg/24 hours)
Number of subjects: 10
Study 22465890 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methyl prednisolone (1000 mg/24 hours) and placebo
Number of subjects: 10
Study 20526703 — intervention group
Group type: EXPERIMENTAL
Intervention: CLD 100 mg IM weekly for 12 months
Number of subjects: 60
Study 20526703 — intervention group
Group type: EXPERIMENTAL
Intervention: CLD 200 mg IM every 2 weeks for 12 months
Number of subjects: 60
Study 17964398 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ IOL
Number of subjects: 25
Study 17964398 — intervention group
Group type: COMPARATOR
Intervention: AcrySof Natural IOL
Number of subjects: 25
Study 11703042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group T
Number of subjects: 0
Study 11703042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group S
Number of subjects: 0
Study 11703042 — intervention group
Group type: COMPARATOR
Intervention: Control group C
Number of subjects: 0
Study 9220520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 92
Study 9220520 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 92
Study 9220520 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy (Control)
Number of subjects: 92
Study 9220520 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ECP > or = 16 micrograms/L
Number of subjects: 92
Study 9220520 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ECP < 16 micrograms/L
Number of subjects: 92
Study 9220520 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ECP > or = 8 micrograms/L
Number of subjects: 92
Study 8427515 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day tiludronate for five days
Number of subjects: 18
Study 8427515 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day tiludronate for five days
Number of subjects: 18
Study 8427515 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg/day tiludronate for five days
Number of subjects: 18
Study 8427515 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 3113413 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion
Number of subjects: 15
Study 3113413 — intervention group
Group type: COMPARATOR
Intervention: Simple electrolyte solutions or isocaloric parenteral regimes without fat emulsion
Number of subjects: 15
Study 3113413 — intervention group
Group type: COMPARATOR
Intervention: Dextrose or amino acid solutions
Number of subjects: 15